Health-Related Quality of Life and Utilities of Respondents with Type 2 Diabetes **Compared with Those with Differing Levels of Cardiometabolic Risk**

Richard H. Chapman¹, Kathleen M. Fox², and Susan Grandy³ ¹ValueMedics Research, Falls Church, VA; ² Strategic Healthcare Solutions, LLC, Monkton, MD; ³ AstraZeneca Pharmaceuticals LP, Wilmington, DE

BACKGROUND

- Diabetes and its complications substantially affect patients' HRQoL¹⁻²
- Limited information available on HRQoL of individuals without diabetes but at high risk of developing this condition
- Generic utility measures such as EQ-5D of relevant populations are necessary inputs for cost-effectiveness analyses that use quality-adjusted life-years
- There is a need to utilize generic HRQoL instruments among patients with diabetes to allow comparisons with populations without diabetes
 - Generic measures are useful in estimating the incremental burden of diabetes compared to those with similar comorbidities and risk factors but without diabetes
- Understanding the impact of diabetes on HRQoL may provide impetus for diabetes education and prevention

OBJECTIVES

- Assess differences in HRQoL among respondents with type 2 diabetes (T2D) and those with varying levels of cardiometabolic risk, using data from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD)
- Provide HRQoL utility estimates for a US adult population at risk of developing diabetes, as well as US adults with T2D

METHODS

Study Design

- Cross-sectional analysis of HRQoL and utility scores from the SHIELD study of adults with or at risk of T2D
- SHIELD is a 5-year longitudinal population-based survey conducted to better understand the burden of illness of people living with diabetes and those at risk for its development

Study Population

Three groups of respondents studied:

- 1. **T2D**: respondents with a reported diagnosis of type 2 diabetes mellitus
- 2. High Risk: respondents with 3-5 cardiometabolic risk factors, which included:
 - a. Abdominal obesity: waist circumference >97 cm in men, >89 cm in women
 - b. BMI ≥28 kg/m²
 - c. Reported diagnosis of cholesterol problems
 - d. Reported diagnosis of high blood pressure
 - e. History of cardiovascular disease
 - Coronary heart disease
 - ii. Myocardial infarction
 - iii. Narrow or blocked arteries
 - iv. Stroke
 - v. Coronary artery bypass graft surgery, angioplasty, stents
- 3. Low Risk: respondents with ≤ 2 of the above risk factors

HRQoL Assessment

- value for health status
- valuations:
 - scores indicating better HRQoL; and
 - for current health
 - 1. Mobility
 - 2. Self-care
 - 3. Usual activities
 - 4. Pain and discomfort 5. Anxiety and depression

Statistical Analyses

- index scores
- Mean EQ-5D VAS and utility scores were computed
- high-risk and low-risk groups
- Statistical significance was selected a priori as p<0.01

RESULTS

A total of 14,995 respondents completed the EQ-5D at baseline

Characteristics	T2D N=3,889	High Risk N=5,425	Low Risk N=5,681
Age, mean (SD)	60.3 (13.1)	58.9 (14.6)*	47.0 (16.4)*
Women, %	2250 (57.9%)	3076 (56.7%)	3725 (65.6%)*
Race, % whites	3302 (84.9%)	4794 (88.4%)*	5014 (88.3%)*
Education, % with some college or higher	2486 (63.9%)	3651 (67.3%)*	4204 (74.0%)*
Income, % with <\$40,000	2052 (52.8%)	2529 (46.6%)*	2079 (36.6%)*
Geographic region, %			
Northeast	774 (19.9%)	1066 (19.6%)	1071 (18.8%)
North Central	914 (23.5%)	1379 (25.4%)	1451 (25.5%)
South Atlantic	824 (21.2%)	1077 (19.9%)	1007 (17.7%)*
South Central	676 (17.4%)	915 (16.9%)	937 (16.5%)
Mountain	213 (5.5%)	313 (5.8%)	405 (7.1%)
Pacific	488 (12.5%)	675 (12.4%)	810 (14.3%)

* p value <0.05 for comparison with T2D

- respondents
- with high- and low-risk respondents

• HRQoL was measured at baseline by the EQ-5D³, which provides a simple descriptive profile of HRQoL and a single utility index

• EQ-5D is a self-reported questionnaire comprising 2 HRQoL

- a visual analog scale recording the respondent's

self-rated, current health status on a 0-100 scale, with higher

- a profile of 5 health dimensions that is converted into an index score representing a von Neumann-Morgenstern utility value

• US population weights were used to compute EQ-5D utility


• ANOVA with Fisher's least significant difference post-hoc testing was performed to compare mean EQ-5D scores across T2D,

• T2D respondents were older compared with high- and low-risk

• A significantly lower proportion of T2D respondents were white, had some college education, and income >\$40,000, compared

EQ-5D Scores

Figure 1. Mean EQ-5D Visual Analog Scale scores by diabetes risk group



*p<0.004, T2D vs. Low risk and High risk vs. Low risk **p<0.004, T2D vs. High risk

- Average VAS scores for T2D and high-risk respondents were substantially lower than low-risk respondents (Fig. 1)
- Average VAS score for T2D respondents was significantly lower than high-risk respondents
- Greater proportion of low-risk (34.5%) respondents rated their current state of health >90 on the VAS, compared with 13.9% of T2D and 17.7% of high-risk respondents
- Similar proportions of T2D and high-risk respondents (~20%) each) reported a health status rating of 70-79, compared with 14.9% of low-risk respondents

Table 2. EQ-5D dimensions of health: Proportion of SHIELD respondents with at least some problem^

Dimension	T2D	High Risk	Low F
Mobility			
N	3,884	5,413	5,67
% with problem	47.9%	43.4%	17.1
Self-care			
Ν	3,876	5,419	5,67
% with problem	8.5%	6.5%	2.7%
Performing usual activities			
N	3,880	5,415	5,66
% with problem	36.1%	33.3%	15.7
Pain or discomfort			
Ν	3,875	5,411	5,67
% with pain/discomfort	61.1%	61.8%	43.5
Anxious or depressed			
N	3,877	5,405	5,66
% anxious/depressed	26.1%	24.9%	19.9

^ % responding some or unable, or moderately/extremely

- T2D and high-risk respondents had similar scores and proportions of individuals with problems on each dimension, with both groups impacted more than the low-risk respondents
- The largest difference among groups was a decrement in mobility: 47.9%, 43.4%, and 17.1% for the T2D and high- and low-risk groups, respectively
- Proportions of respondents reporting some problems with washing and dressing self were generally low across all groups, although higher in T2D and high-risk groups, compared with low-risk group
- A greater proportion of T2D (10.5%) and high-risk (9.4%) respondents also reported extreme pain or discomfort, compared with low-risk respondents (4.2%)

ð

SC

0.1

EQ-5D Utility Scores

Risk 73 1%

61 9%

0.870 0.9 0.792* 0.8 0.778** 0.7 0.6 Low risk 0.5 High risk T2D 0.4 0.3 0.2

Figure 2. Mean EQ-5D Utility Index scores by diabetes risk group

*p<0.004. T2D vs. Low risk and High risk vs. Low risk **p<0.004. T2D vs. High risk

- Average EQ-5D utility scores for T2D and high-risk respondents were substantially lower than for low-risk respondents (Fig. 2)
- Average utility score for T2D respondents was significantly lower than the mean score for high-risk respondents

LIMITATIONS

• Household panels, like the SHIELD study, tend to under-represent the very wealthy and very poor segments of the population and do not include military or institutionalized individuals

SUMMARY/CONCLUSIONS

- EQ-5D scores, whether measured by VAS or utility index, were substantially higher in the respondents with low cardiometabolic risk than those in the high cardiometabolic risk or T2D groups
- Respondents with low cardiometabolic risk had the lowest proportion of self-reported difficulties in all 5 health dimensions, compared with respondents with T2D or high cardiometabolic risk
- T2D and high-risk groups had similar health profiles and overall scores, although T2D respondents had lower overall **HRQoL**
- In conclusion, even without a diagnosis of diabetes mellitus, those at high cardiometabolic risk experienced decreased HRQoL
- Reducing cardiometabolic risk factors may lead to significant improvements in HRQoL even before diabetes is diagnosed

h	Abbreviations			
•••	Abbreviation	Definition		
	ANOVA	Analysis of Variance		
	BMI	Body mass index		
1	EQ-5D	EuroQoL - 5 dimensions		
1	HRQoL	Health-related quality of life		
	SHIELD	Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes		
g	T2D	Type 2 diabetes		
	VAS	Visual analog scale		
)	Reference	S Value in Health 2000; 3(Suppl 1): 15-28.		

- $_{\rm L}$ uscompe FA. value in mealth 2000, 3(Suppl T). 2. Garratt AM et al. Diabetic Medicine 2002; 19:1-11.
- 3. Rabin R. de Charro F. Ann Med 2001: 33:337-343

This research was supported by AstraZeneca Pharmaceuticals LP Presented at the ISPOR 12th Annual International Meeting, May 19-23, 2007, Arlington, VA, USA